MENU
+Compare
OTLK
Stock ticker: NASDAQ
AS OF
May 22 closing price
Price
$1.64
Change
+$0.01 (+0.61%)
Capitalization
55.05M

OTLK Outlook Therapeutics Forecast, Technical & Fundamental Analysis

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications... Show more

Industry: #Biotechnology
OTLK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for OTLK with price predictions
May 21, 2025

OTLK saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for OTLK moved out of overbought territory on May 15, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 49 similar instances where the indicator exited the overbought zone. In of the 49 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for OTLK moved out of overbought territory on May 14, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OTLK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

OTLK broke above its upper Bollinger Band on May 13, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 09, 2025. You may want to consider a long position or call options on OTLK as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for OTLK just turned positive on May 12, 2025. Looking at past instances where OTLK's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

OTLK moved above its 50-day moving average on May 08, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for OTLK crossed bullishly above the 50-day moving average on April 25, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OTLK advanced for three days, in of 248 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 154 cases where OTLK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. OTLK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (16.453). P/E Ratio (0.401) is within average values for comparable stocks, (59.882). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.200). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (281.707).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OTLK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
OTLK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

OTLK is expected to report earnings to fall 34.44% to -98 cents per share on May 15

Outlook Therapeutics OTLK Stock Earnings Reports
Q1'24
Est.
$-0.98
Q1'25
Missed
by $1.44
Q4'23
Beat
by $0.19
Q3'23
Missed
by $0.94
Q2'23
Missed
by $1.55
The last earnings report on May 15 showed earnings per share of -150 cents, missing the estimate of -5 cents. With 869.58K shares outstanding, the current market capitalization sits at 55.05M.
A.I. Advisor
published General Information

General Information

a manufacturer of biosimilar versions of biopharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
485 Route 1 South Building F
Phone
+1 609 619-3990
Employees
24
Web
https://www.outlooktherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SE163.260.85
+0.52%
Sea Limited
BFAM122.99-0.57
-0.46%
Bright Horizons Family Solutions
CRWS3.18-0.11
-3.20%
Crown Crafts
NVTS1.91-0.09
-4.50%
Navitas Semiconductor Corp
DVAX9.90-0.52
-4.99%
Dynavax Technologies Corp

OTLK and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, OTLK has been loosely correlated with CYTK. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if OTLK jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OTLK
1D Price
Change %
OTLK100%
-4.12%
CYTK - OTLK
33%
Loosely correlated
-4.13%
PDSB - OTLK
33%
Loosely correlated
-3.07%
MCRB - OTLK
32%
Poorly correlated
-6.55%
VIR - OTLK
31%
Poorly correlated
-4.65%
ALXO - OTLK
30%
Poorly correlated
-4.62%
More